Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106778 · ClinicalTrials.gov registry record · Phase 2
DMT310-003 Topical in the Treatment of Acne Vulgaris
A Phase 2 study, sponsored by Dermata Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT04106778: Completed Phase 2 study, sponsored by Dermata Therapeutics.
NCT04106778 is a Phase 2 study that has completed, run by Dermata Therapeutics. The registered enrollment target is 181 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04106778, a Phase 2 study, has completed, sponsored by Dermata Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
Primary Outcome
Inflammatory and Noninflammatory
Interventions
- DRUG Placebo
- DRUG DMT310
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2019-10-10 |
| Est. Completion | 2020-05-04 |
| Phase | Phase 2 |
What the finished NCT04106778 record still lists
NCT04106778 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04106778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04106778 about?
NCT04106778 is a clinical study titled "DMT310-003 Topical in the Treatment of Acne Vulgaris". The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
What is the current status of trial NCT04106778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2019-10-10. Estimated completion is 2020-05-04.
What interventions are being tested in trial NCT04106778?
The interventions under investigation include: Placebo (DRUG), DMT310 (DRUG).
Who is sponsoring clinical trial NCT04106778?
This trial is sponsored by Dermata Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04106778's enrollment target sits among peer trials
181 365th of 2000 higher than 1,636 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI